Uncoupling of VEGF with endothelial NO as a potential mechanism for abnormal angiogenesis in the diabetic nephropathy

Journal of Diabetes Research

Volumn 2013, Issue , 2013, Pages

  Nakagawa, Takahiko ^a   Sato, Waichi ^b   Kosugi, Tomoki ^b   Johnson, Richard J ^c  

^a KYOTO UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; VASCULOTROPIN A;

ANIMAL; DIABETIC NEPHROPATHY; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; TRANSLATIONAL RESEARCH; VASCULAR ENDOTHELIUM;

ANIMALS; DIABETIC NEPHROPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; TRANSLATIONAL MEDICAL RESEARCH; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84893774957     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2013/184539     Document Type: Review

References (55)

1. Østerby R., Nyberg G., New vessel formation in the renal corpuscles in advanced diabetic glomerulopathy. Journal of Diabetic Complications 1987 1 4 122 127 2-s2.0-0023429720
2. Hohenstein B., Hausknecht B., Boehmer K., Riess R., Brekken R. A., Hugo C. P. M., Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney International 2006 69 9 1654 1661 2-s2.0-33646501496 10.1038/sj.ki.5000294
3. Kanesaki Y., Suzuki D., Uehara G., Toyoda M., Katoh T., Sakai H., Watanabe T., Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. The American Journal of Kidney Diseases 2005 45 2 288 294 2-s2.0-15944376565 10.1053/j.ajkd.2004.09.020 (Pubitemid 40431054)
4. Østerby R., Bangstad H.-J., Nyberg G., Rudberg S., On glomerular structural alterations in type-1 diabetes: companions of early diabetic glomerulopathy. Virchows Archiv 2001 438 2 129 135 2-s2.0-0035111630 10.1007/s004280000311 (Pubitemid 32186580)
5. Min W., Yamanaka N., Three-dimensional analysis of increased vasculature around the glomerular vascular pole in diabetic nephropathy. Virchows Archiv A 1993 423 3 201 207 2-s2.0-0027379945 (Pubitemid 23309335)
6. Wehner H., Nelischer G., Morphometric investigations on intrarenal vessels of streptozotocin-diabetic rats. Virchows Archiv A 1991 419 3 231 235 2-s2.0-0026095917
7. Østerby R., Hartmann A., Bangstad H.-J., Structural changes in renal arterioles in type I diabetic patients. Diabetologia 2002 45 4 542 549 2-s2.0-0035988186 10.1007/s00125-002-0780-2 (Pubitemid 34533833)
8. Nyengaard J. R., Rasch R., The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes. Diabetologia 1993 36 3 189 194 2-s2.0-0027408091 (Pubitemid 23067077)
9. Guo M., Ricardo S. D., Deane J. A., Shi M., Cullen-McEwen L., Bertram J. F., A stereological study of the renal glomerular vasculature in the db/db mouse model of diabetic nephropathy. Journal of Anatomy 2005 207 6 813 821 2-s2.0-29644434152 10.1111/j.1469-7580.2005.00492.x (Pubitemid 43019739)
10. Ichinose K., Maeshima Y., Yamamoto Y., Kinomura M., Hirokoshi K., Kitayama H., Takazawa Y., Sugiyama H., Yamasaki Y., Agata N., Makino H., 2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes 2006 55 5 1232 1242 2-s2.0-33745299881 10.2337/diabetes. (Pubitemid 44195359)
11. Baelde H. J., Eikmans M., Lappin D. W. P., Doran P. P., Hohenadel D., Brinkkoetter P.-T., Van Der Woude F. J., Waldherr R., Rabelink T. J., De Heer E., Bruijn J. A., Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney International 2007 71 7 637 645 2-s2.0-33846669530 10.1038/sj.ki.5002101 (Pubitemid 46494557)
12. Nakagawa T., Sato W., Glushakova O., Heinig M., Clarke T., Campbell-Thompson M., Yuzawa Y., Atkinson M. A., Johnson R. J., Croker B., Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. Journal of the American Society of Nephrology 2007 18 2 539 550 2-s2.0-33846701668 10.1681/ASN.2006050459 (Pubitemid 46193319)
13. Ostendorf T., Kunter U., Eitner F., Loos A., Regele H., Kerjaschki D., Henninger D. D., Janjic N., Floege J., VEGf165 mediates glomerular endothelial repair. Journal of Clinical Investigation 1999 104 7 913 923 2-s2.0-0032589378 (Pubitemid 29536341)
14. Kang D.-H., Hughes J., Mazzali M., Schreiner G. F., Johnson R. J., Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. Journal of the American Society of Nephrology 2001 12 7 1448 1457 2-s2.0-0034917262 (Pubitemid 32666327)
15. Kang D.-H., Kim Y.-G., Andoh T. F., Gordon K. L., Suga S.-I., Mazzali M., Jefferson J. A., Hughes J., Bennett W., Schreiner G. F., Johnson R. J., Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor. The American Journal of Physiology-Renal Physiology 2001 280 4 F727 F736 2-s2.0-14344270356
16. Cooper M. E., Vranes D., Youssef S., Stacker S. A., Cox A. J., Rizkalla B., Casley D. J., Bach L. A., Kelly D. J., Gilbert R. E., Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999 48 11 2229 2239 2-s2.0-0032712434 10.2337/diabetes.48.11.2229 (Pubitemid 29521855)
17. Sato W., Kosugi T., Zhang L., Roncal C. A., Heinig M., Campbell-Thompson M., Yuzawa Y., Atkinson M. A., Grant M. B., Croker B. P., Nakagawa T., The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy. Laboratory Investigation 2008 88 9 949 961 2-s2.0-50249148344 10.1038/labinvest.2008.60
18. Kim N. H., Oh J. H., Seo J. A., Lee K. W., Kim S. G., Choi K. M., Baik S. H., Choi D. S., Kang Y. S., Han S. Y., Han K. H., Ji Y. H., Cha D. R., Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney International 2005 67 1 167 177 2-s2.0-19944419453 10.1111/j.1523-1755.2005.00067.x (Pubitemid 40019238)
19. de Vriese A. S., Tilton R. G., Elger M., Stephan C. C., Kriz W., Lameire N. H., Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. Journal of the American Society of Nephrology 2001 12 5 993 1000 2-s2.0-0035034655 (Pubitemid 32378340)
20. Schrijvers B. F., de Vriese A. S., Tilton R. G., van de Voorde J., Denner L., Lameire N. H., Flyvbjerg A., Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes. Hormone and Metabolic Research 2005 37 1 21 25 2-s2.0-13944274471 10.1055/s-2005-861027 (Pubitemid 40269447)
21. Ku C.-H., White K. E., Cas A. D., Hayward A., Webster Z., Bilous R., Marshall S., Viberti G., Gnudi L., Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes 2008 57 10 2824 2833 2-s2.0-58149343883 10.2337/db08-0647
22. Zhao Q., Egashira K., Inoue S., Usui M., Kitamoto S., Ni W., Ishibashi M., Hiasa K.-I., Ichiki T., Shibuya M., Takeshita A., Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation 2002 105 9 1110 1115 2-s2.0-0037022863 10.1161/hc0902.104718 (Pubitemid 34212623)
23. Dunk C., Ahmed A., Vascular endothelial growth factor receptor-2-mediated mitogenesis is negatively regulated by vascular endothelial growth factor receptor-1 in tumor epithelial cells. The American Journal of Pathology 2001 158 1 265 273 2-s2.0-0035145030 (Pubitemid 32096492)
24. Brodsky S. V., Morrishow A. M., Dharia N., Gross S. S., Goligorsky M. S., Glucose scavenging of nitric oxide. The American Journal of Physiology-Renal Physiology 2001 280 3 F480 F486 2-s2.0-0034980789
25. Bucala R., Tracey K. J., Cerami A., Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. Journal of Clinical Investigation 1991 87 2 432 438 2-s2.0-0026062122
26. Khosla U. M., Zharikov S., Finch J. L., Nakagawa T., Roncal C., Mu W., Krotova K., Block E. R., Prabhakar S., Johnson R. J., Hyperuricemia induces endothelial dysfunction. Kidney International 2005 67 5 1739 1742 2-s2.0-20244365646 10.1111/j.1523-1755.2005.00273.x (Pubitemid 40577708)
27. Xiong Y., Lei M., Fu S., Fu Y., Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes. Life Sciences 2005 77 2 149 159 2-s2.0-18044377957 10.1016/j.lfs.2004.10.062 (Pubitemid 40603500)
28. Ceriello A., Mercuri F., Quagliaro L., Assaloni R., Motz E., Tonutti L., Taboga C., Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 2001 44 7 834 838 2-s2.0-0034937703 10.1007/s001250100529 (Pubitemid 32642455)
29. Noiri E., Satoh H., Taguchi J.-I., Brodsky S. V., Nakao A., Ogawa Y., Nishijima S., Yokomizo T., Tokunaga K., Fujita T., Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension 2002 40 4 535 540 2-s2.0-0036791822 10.1161/01.HYP.0000033974.57407.82
30. Liu Y., Burdon K. P., Langefeld C. D., Beck S. R., Wagenknecht L. E., Rich S. S., Bowden D. W., Freedman B. I., T-786C polymorphism of the endothelial nitric oxide synthase gene is associated with albuminuria in the diabetes heart study. Journal of the American Society of Nephrology 2005 16 4 1085 1090 2-s2.0-24344495518 10.1681/ASN.2004100817 (Pubitemid 41710319)
31. Neugebauer S., Baba T., Watanabe T., Association of the nitric oxide synthase gene polymorphism with an increased risk for progression to diabetic nephropathy in type 2 diabetes. Diabetes 2000 49 3 500 503 2-s2.0-0034007216 (Pubitemid 30131798)
32. Shin Shin Y., Baek S. H., Chang K. Y., Park C. W., Yang C. W., Jin D. C., Kim Y. S., Chang Y. S., Bang B. K., Relations between eNOS Glu298Asp polymorphism and progression of diabetic nephropathy. Diabetes Research and Clinical Practice 2004 65 3 257 265 2-s2.0-4344619822 10.1016/j.diabres.2004.01. 010 (Pubitemid 39141182)
33. Zanchi A., Moczulski D. K., Hanna L. S., Wantman M., Warram J. H., Krolewski A. S., Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney International 2000 57 2 405 413 2-s2.0-0033917346 10.1046/j.1523-1755.2000. 00860.x (Pubitemid 30430632)
34. Degen B., Schmidt S., Ritz E., A polymorphism in the gene for the endothelial nitric oxide synthase and diabetic nephropathy. Nephrology Dialysis Transplantation 2001 16 1 185 2-s2.0-0035160058 (Pubitemid 32051503)
35. Lin S., Qu H., Qiu M., Allele A in intron 4 of ecNOS gene will not increase the risk of diabetic nephropathy in type 2 diabetes of Chinese population. Nephron 2002 91 4 768 2-s2.0-0036688683 10.1159/000065048 (Pubitemid 34914089)
36. Rippin J. D., Patel A., Belyaev N. D., Gill G. V., Barnett A. H., Bain S. C., Nitric oxide synthase gene polymorphisms and diabetic nephropathy. Diabetologia 2003 46 3 426 428 2-s2.0-0038303081 (Pubitemid 36547600)
37. Shimizu T., Onuma T., Kawamori R., Makita Y., Tomino Y., Endothelial nitric oxide synthase gene and the development of diabetic nephropathy. Diabetes Research and Clinical Practice 2002 58 3 179 185 2-s2.0-0036972917 10.1016/S0168-8227(02)00156-0 (Pubitemid 36159014)
38. Hohenstein B., Hugo C. P. M., Hausknecht B., Boehmer K. P., Riess R. H., Schmieder R. E., Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy. Nephrology Dialysis Transplantation 2008 23 4 1346 1354 2-s2.0-42949117941 10.1093/ndt/gfm797 (Pubitemid 351767511)
39. Sugimoto H., Shikata K., Matsuda M., Kushiro M., Hayashi Y., Hiragushi K., Wada J., Makino H., Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 1998 41 12 1426 1434 2-s2.0-0031773118 10.1007/s001250051088 (Pubitemid 28551613)
40. Brodsky S. V., Gao S., Li H., Goligorsky M. S., Hyperglycemic switch from mitochondrial nitric oxide to superoxide production in endothelial cells. The American Journal of Physiology-Heart and Circulatory Physiology 2002 283 5 H2130 H2139 2-s2.0-0036838636 (Pubitemid 35217047)
41. Komers R., Schutzer W. E., Reed J. F., Lindsley J. N., Oyama T. T., Buck D. C., Mader S. L., Anderson S., Altered endothelial nitric oxide synthase targeting and conformation and caveolin-1 expression in the diabetic kidney. Diabetes 2006 55 6 1651 1659 2-s2.0-33748307456 10.2337/db05-1595 (Pubitemid 44324117)
42. Borch-Johnsen K., Kreiner S., Deckert T., Mortality of type 1 (insulin-dependent) diabetes mellitus in Denmark: a study of relative mortality in 2930 Danish type 1 diabetic patients diagnosed from 1933 to 1972. Diabetologia 1986 29 11 767 772 2-s2.0-0022913068 (Pubitemid 17053712)
43. Nakagawa T., Sato W., Sautin Y. Y., Glushakova O., Croker B., Atkinson M. A., Tisher C. C., Johnson R. J., Uncoupling of vascular endothelial growth factor with nitric oxide as a mechanism for diabetic vasculopathy. Journal of the American Society of Nephrology 2006 17 3 736 745 2-s2.0-33645456312 10.1681/ASN.2005070759
44. Sato W., Tanabe K., Kosugi T., Hudkins K., Lanaspa M. A., Zhang L., Campbell-Thompson M., Li Q., Long D. A., Alpers C. E., Nakagawa T., Selective stimulation of VEGFR2 accelerates progressive renal disease. The American Journal of Pathology 2011 179 1 155 166 2-s2.0-80052475033 10.1016/j.ajpath. 2011.03.024
45. Grone H.-J., Simon M., Grone E. F., Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. The Journal of Pathology 1995 177 3 259 267 2-s2.0-0028848487 10.1002/path.1711770308
46. Shulman K., Rosen S., Tognazzi K., Manseau E. J., Brown L. F., Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. Journal of the American Society of Nephrology 1996 7 5 661 666 2-s2.0-0030357278 (Pubitemid 27465997)
47. Sivaskandarajah G. A., Jeansson M., Maezawa Y., Eremina V., Baelde H. J., Quaggin S. E., Vegfa protects the glomerular microvasculature in diabetes. Diabetes 2012 61 11 2958 2966
48. Kosugi T., Heinig M., Nakayama T., Matsuo S., Nakagawa T., eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists. The American Journal of Pathology 2010 176 2 619 629 2-s2.0-76149086524 10.2353/ajpath.2010.090578
49. Perico N., Amuchastegui S. C., Colosio V., Sonzogni G., Bertani T., Remuzzi G., Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. Journal of the American Society of Nephrology 1994 5 4 1139 1146 2-s2.0-0028522446 (Pubitemid 24977093)
50. Pichaiwong W., Hudkins K. L., Wietecha T., Reversibility of structural and functional damage in a model of advanced diabetic nephropathy. Journal of the American Society of Nephrology 2013 24 7 1088 1102
51. Tanabe K., Lanaspa M. A., Kitagawa W., Rivard C. J., Miyazaki M., Klawitter J., Schreiner G. F., Saleem M. A., Mathieson P. W., Makino H., Johnson R. J., Nakagawa T., Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse. The American Journal of Physiology-Renal Physiology 2012 302 9 F1151 F1161 2-s2.0-84860540851 10.1152/ajprenal.00596.2011
52. Imanishi M., Okada N., Konishi Y., Angiotensin II receptor blockade reduces salt sensitivity of blood pressure through restoration of renal nitric oxide synthesis in patients with diabetic nephropathy. Journal of the Renin-Angiotensin-Aldosterone System 2013 14 1 67 73
53. Fioretto P., Stehouwer C. D. A., Mauer M., Chiesura-Corona M., Brocco E., Carraro A., Bortoloso E., Van Hinsbergh V. W. M., Crepaldi G., Nosadini R., Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure. Diabetologia 1998 41 2 233 236 2-s2.0-6844252285 10.1007/s001250050895 (Pubitemid 28088402)
54. Jensen T., Increased plasma concentration of von Willebrand factor in insulin dependent diabetics with incipient nephropathy. The British Medical Journal 1989 298 6665 27 28 2-s2.0-0024552718 (Pubitemid 19022886)
55. Jensen T., Bjerre-Knudsen J., Feldt-Rasmussen B., Deckert T., Features of endothelial dysfunction in early diabetic nephropathy. The Lancet 1989 1 8636 461 463 2-s2.0-0024550328 (Pubitemid 19063530)